Kalaris Therapeutics, Inc. Executive Compensation (FY25)
KLRS · Executive and director compensation, fiscal 2024 to 2025
The Kalaris Therapeutics, Inc. brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Data as of September 27, 2026Latest filing (DEF 14A): April 24, 2026
1 filing cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
The Pay Desk is the free weekly executive pay briefing — one company at a time, every number traceable to a public filing.You’ll confirm on The Pay Desk’s sign-up page.
$1,500Get the executive brief
89 figures on this page, cited to the filing that reported them. See the citations
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Andrew Oxtoby: $1,965,153 → $2,569,115 (30.7% higher)
Frequently asked questions
Answers drawn from the data on this page.
Who is Kalaris Therapeutics, Inc.'s chief executive and what were they paid?
Andrew Oxtoby was paid $2,569,115 in total compensation as President and Chief Executive Officer for fiscal 2025. Oxtoby's total moved 30.7% higher from the $1,965,153 reported for fiscal 2024.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Andrew Oxtoby President and Chief Executive Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Brett Hagen Chief Accounting Officer and AlloVir’s former Chief Accounting Officer | ◇ | ◇ | — | — | — | — | ◇ | ◇ |
Vikas Sinha AlloVir’s Former Chief Executive Officer, President and Chief Financial Officer | ◇ | — | — | — | ◇ | — | — | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Andrew Oxtoby President and Chief Executive Officer | ◇ | — | — | ◇ | ◇ | — | — | ◇ |
Matthew Feinsod Chief Medical Officer | ◇ | — | — | ◇ | ◇ | — | — | ◇ |
Brett Hagen Chief Accounting Officer and AlloVir’s former Chief Accounting Officer Departed during or after this year | ◇ | ◇ | — | ◇ | ◇ | — | ◇ | ◇ |
Vikas Sinha AlloVir’s Former Chief Executive Officer, President and Chief Financial Officer Departed during or after this year | ◇ | — | — | — | — | — | ◇ | ◇ |
Matthew Gall Former Chief Financial Officer Departed during or after this year | ◇ | — | — | ◇ | ◇ | — | — | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Brett Hagen | Option | ◇ | — | ◇ | 4/9/2035 |
| Matthew Feinsod | Option | ◇ | — | ◇ | 4/9/2035 |
| Option | ◇ | — | ◇ | 7/22/2034 | |
| Option | ◇ | — | ◇ | 4/9/2035 | |
| Andrew Oxtoby | Option | ◇ | — | ◇ | 4/9/2035 |
| Option | ◇ | — | ◇ | 5/27/2034 | |
| Matthew Gall | Option | ◇ | — | ◇ | 11/2/2035 |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
David Hallal Board chair | ◇ | — | ◇ | — | — | — | ◇ |
Morana Jovan-Embiricos, Ph.D | ◇ | — | ◇ | — | — | — | ◇ |
Napoleone Ferrara, M.D | ◇ | — | ◇ | — | — | ◇ | ◇ |
Leone Patterson | ◇ | — | ◇ | — | — | — | ◇ |
Michael Dybbs, Ph.D | ◇ | — | ◇ | — | — | — | ◇ |
Anthony P. Adamis, M.D | ◇ | — | ◇ | — | — | ◇ | ◇ |
Srinivas Akkaraju, M.D., Ph.D | ◇ | — | ◇ | — | — | — | ◇ |
Jeffrey S. Bornstein | ◇ | — | — | — | — | — | ◇ |
Shawn Tomasello | ◇ | — | — | — | — | — | ◇ |
Derek Adams, Ph.D | ◇ | — | — | — | — | — | ◇ |
Malcolm Brenner, M.D., Ph.D | ◇ | — | — | — | — | — | ◇ |
Juan Vera, M.D | ◇ | — | — | — | — | — | ◇ |
Andrew Oxtoby served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Total board retainer | ◇ |
| Board chair premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Equity is delivered as Options.
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Velarion Pro: every company page, peer tools and exports, one seat
One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
What this page does not include
Everything above is a fact Kalaris Therapeutics, Inc. disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
89 figures on this page, cited to the filing that reported them.
89 cited to the filing
Documents cited
- 0001193125-26-177362Director Compensation · Outstanding Equity Awards at 2025 Fiscal Year-End · Summary Compensation Table
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Kalaris Therapeutics, Inc. executive compensation, FY2024–FY2025.” https://intel.velarion.ai/comp/KLRS (accessed 2026).
Short form: data: Velarion
The Kalaris Therapeutics, Inc. brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
1 filing cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Kalaris Therapeutics, Inc. and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}